Clinical Trials Logo
  1. Home
  2. Type 1 Diabetes
  3. NCT00945711
  4. Details
NCT00945711 Clinical Trial

Characteristics of Persons With an Eating Disorder and Type 1 Diabetes

Type 1 Diabetes Clinical Trial

Official title:
Characteristics of Persons With an Eating Disorder and Type 1 Diabetes and Psychological Comparisons to Persons With an Eating Disorder and No Diabetes

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00945711
Other study ID # 03802-08-C
Secondary ID
Status Completed
Phase N/A
First received July 22, 2009
Last updated November 30, 2015
Start date March 2010
Est. completion date September 2010

Study information
Verified date August 2013
Source HealthPartners Institute
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

The purpose of this study is to analyze a chart audit of patients seen at Park Nicollet Eating Disorder Institute (EDI) to identify and compare general characteristics of eating disorders with type 1 diabetes patients to a matched eating disordered population without type 1 diabetes, also seen at EDI.

Description:

The goal of this study is to conduct a chart audit on all patients with type 1 diabetes who have been seen collaboratively by International Diabetes Center (IDC) and Park Nicollet Eating Disorder Institute (EDI) staff from 2005 - 2008 and their matched eating disordered controls.

Research Questions

1. What are the general characteristics of the ED DM T1 population?

2. How are ED DM T1 patients different from the matched eating disordered patients with respect to race, marital status, age of onset, eating behaviors, self-reported highest and lowest weight, exercise frequency and duration, number of hospital admissions, number of emergency room visits, medication needs, and other medical and psychological/psychiatric comorbidities?

3. How are ED DM T1 patients different from the matched eating disordered patients with respect to the affective and cognitive aspects of eating disorders such as self-reported depression symptoms, body image distortion, thoughts and feelings about eating, psychological concerns, readiness to change, self-esteem and anxiety?

4. For ED DM T1 patients, what is the time relationship of the diagnosis of diabetes and an eating disorder?

5. For ED DM T1 patients, what is the relationship of BMI and A1c?

Recruitment information / eligibility
Status Completed
Enrollment 154
Est. completion date September 2010
Est. primary completion date September 2010
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- patient seen in both Park Nicollet Eating Disorder Institute and International Diabetes Center for type 1 diabetes from 2005 - 2008

- patient seen only in Park Nicollet Eating Disorder Institute from 2005 - 2008

Exclusion Criteria:

Study Design

Observational Model: Case Control, Time Perspective: Retrospective

Related Conditions & MeSH terms

Locations
Country Name City State
United States International Diabetes Center Minneapolis Minnesota

Sponsors (4)
Lead Sponsor Collaborator
HealthPartners Institute International Diabetes Center at Park Nicollet, Park Nicollet Eating Disorder Institute, Park Nicollet Foundation

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary define general characteristics of the diabetes and eating disorder population 2005 - 2008 No
See also
  Status Clinical Trial Phase
Recruiting NCT05653518 - Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes N/A
Enrolling by invitation NCT05515939 - Evaluating the InPen in Pediatric Type 1 Diabetes
Completed NCT05109520 - Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
Recruiting NCT04016987 - Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes N/A
Active, not recruiting NCT04190368 - Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes N/A
Recruiting NCT05413005 - Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus Early Phase 1
Active, not recruiting NCT04668612 - Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes N/A
Completed NCT02837094 - Enhanced Epidermal Antigen Specific Immunotherapy Trial -1 Phase 1
Recruiting NCT05414409 - The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action Phase 2
Recruiting NCT05670366 - The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes N/A
Active, not recruiting NCT05418699 - Real-life Data From Diabetic Patients on Closed-loop Pumps
Completed NCT04084171 - Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6 N/A
Recruiting NCT06144554 - Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
Recruiting NCT05153070 - Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes Phase 2
Recruiting NCT05379686 - Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes N/A
Completed NCT05281614 - Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D Early Phase 1
Withdrawn NCT04259775 - Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes N/A
Active, not recruiting NCT01600924 - Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
Completed NCT02750527 - Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany
Completed NCT02855307 - Closed-loop Control of Glucose Levels (Artificial Pancreas) During Postprandial Exercise in Adults With Type 1 Diabetes Phase 2